About

Lorenzo Dutto is a leading urological surgeon and researcher whose work centers on improving outcomes for men with localized prostate cancer, with a particular focus on precision surgery, functional recovery, and imaging accuracy. His most impactful contribution is the landmark NeuroSAFE PROOF trial (2025), a multicentre, patient-blinded, randomized phase 3 study demonstrating that NeuroSAFE-guided robot-assisted radical prostatectomy (RARP) significantly improves erectile function and early urinary continence compared to standard RARP—a finding with direct implications for quality of life after cancer treatment. Dutto has also advanced preoperative staging: his 2022 study on negative multiparametric MRI (mpMRI) showed it can reliably rule out extra-prostatic extension, helping avoid unnecessary nerve damage. Additionally, his 2021 work comparing imaging and clinical methods for estimating prostate volume (42 citations) provides practical guidance for risk stratification. With over 160 cumulative citations, Dutto’s research bridges surgical innovation and patient-reported outcomes, making him a key figure in modern, nerve-sparing robotic prostate cancer surgery.

Research Focus

Key Achievements

6
H-Index
9
Papers
167
Total Citations
19
Avg Citations/Paper
🏆 Most Cited Paper
The Comparison of Imaging and Clinical Methods to Estimate Prostate Volume: A Single-Centre Retrospective Study
42 citations · 2021
📈 Most Prolific Year: 2022 (3 Papers)
🤝 Key Collaborators: 73
🏛 Institutions: Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Cork University Hospital, Queen Elizabeth Hospital, St.-Antonius-Hospital Gronau

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago